As of November 9, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Passage BIO, Inc. The largest reported stake is Lynx1 Capital Management LP's, at 21%. 7 filings are on record since July 9, 2025 (Schedule 13D, July 2, 2026).
Sell to companies like Passage BIO, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Lynx1 Capital Management LP · Sole voting: 0 · Shared voting: 673,759 · Sole dispositive: 0 · Shared dispositive: 673,759 · SCHEDULE 13D, 2026-07-02
- · Reporting person: Baselake Partners, LP · Sole voting: 0 · Shared voting: 235,058 · Sole dispositive: 0 · Shared dispositive: 235,058 · SCHEDULE 13G, 2026-06-25
- · Holder: Lynx1 Capital Management LP · Percent: 19.6% · SCHEDULE 13G/A
- · Holder: Orbimed Advisors LLC · Percent: 4.25% · SCHEDULE 13D/A
Passage BIO, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-09. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-04-28 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 21% | 673,759 | SCHEDULE 13D, 2026-07-02 | 2026-06-25 |
| Baselake Partners, LP | 7.3% | 235,058 | SCHEDULE 13G, 2026-06-25 | 2026-06-18 |
| Orbimed Advisors LLC | 4.25% | 132,473 | SCHEDULE 13D/A, 2025-07-24 | 2025-07-22 |
| Vestal Point Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind Passage BIO, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Passage BIO, Inc. and the records around it.
Passage BIO, Inc. elsewhere on the record
- Layoff notices Apr 2026
- Who owns it
Companies that share a holder
- Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Generation Bio Co. (Feb 2026), Athira Pharma, Inc. (Feb 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Watch Passage BIO, Inc.
Get an email when Passage BIO, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Passage BIO, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Passage BIO, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Passage BIO, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 0 | 673,759 | 0 | 673,759 | SCHEDULE 13D, 2026-07-02 |
| Weston Nichols | 0 | 673,759 | 0 | 673,759 | SCHEDULE 13D, 2026-07-02 |
| Baselake Partners, LP | 0 | 235,058 | 0 | 235,058 | SCHEDULE 13G, 2026-06-25 |
| Baselake Management, LLC | 0 | 235,058 | 0 | 235,058 | SCHEDULE 13G, 2026-06-25 |
| David Paolella | 0 | 235,058 | 0 | 235,058 | SCHEDULE 13G, 2026-06-25 |
| Vestal Point Capital, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
| Ryan Wilder | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Passage BIO, Inc. by CUSIP 702712209 and gives its principal executive office as One Commerce Square, 2005 Market Street, 39th Floor, PHILADELPHIA, PA 19103 (SCHEDULE 13G/A, 2026-08-14).
Source of funds (Item 3)
Funds for the purchase of the securities reported herein were derived from the general working capital of the Lynx1 Fund. A total of approximately $11,444,608 was paid to acquire such securities. Positions in the shares of Common Stock may be held in margin accounts. Because other securities may be held in such margin accounts, it may not be possible to determine the amounts, if any, of margin used to purchase the shares of Common Stock.Lynx1 Capital Management LP, SCHEDULE 13D, 2026-07-02
Purpose of Transaction (Item 4)
Orbimed Advisors LLC
The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-07-24; the filing has the rest
Lynx1 Capital Management LP
The Reporting Persons originally acquired the securities reported herein because they believe the securities are undervalued and represent an attractive investment opportunity and they continue to hold the shares of Common Stock reported herein for investment purposes. The Reporting Persons previously reported their beneficial ownership on Schedule 13G pursuant to Rule 13d-1(c) under the Act. As a result of the acquisition of additional shares of Common Stock described in Items 3 and 5(c), the Reporting Persons' aggregate beneficial ownership has equaled or exceeded 20% of the outstanding Common Stock. Accordingly, the Reporting Persons are no longer eligible to report on Schedule 13G under Rule 13d-1(c)(3) and are filing this Schedule 13D pursuant to Rule 13d-1(f)(1). On June 24, 2026, the Issuer, Peregrine Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Issuer ("Merger Sub"), and Remix Therapeutics, Inc., a Delaware corporation ("Remix") entered into an Agreement and Plan of Merger (the "Merger Agreement") substantially in the form attached as Exhibit 99.2 to this Schedule 13D, pursuant to which Merger Sub will merge with and into Remix, with Remix surviving the merger and becoming a wholly owned subsidiary of the Issuer (the "Merger"). Following the Merger, the combined company is expected to be renamed "Remix Therapeutics, Inc." and to trade on Nasdaq under the symbol "RMTX." In connection with the Merger, the Lynx1 Fund has agreed …The first part of Item 4 of the SCHEDULE 13D filed 2026-07-02; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-09 | Orbimed Advisors LLC | 9.5% | SCHEDULE 13D/A |
| 2025-07-21 | Orbimed Advisors LLC | 7.82% | SCHEDULE 13D/A |
| 2025-07-24 | Orbimed Advisors LLC | 4.25% | SCHEDULE 13D/A |
| 2025-11-14 | Lynx1 Capital Management LP | 19.6% | SCHEDULE 13G/A |
| 2026-06-25 | Baselake Partners, LP | 7.3% | SCHEDULE 13G |
| 2026-07-02 | Lynx1 Capital Management LP | 21% | SCHEDULE 13D |
| 2026-08-14 | Vestal Point Capital, LP | 0% | SCHEDULE 13G/A |
Questions about who owns Passage BIO, Inc.
Who owns Passage BIO, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Passage BIO, Inc.: Lynx1 Capital Management LP (21%, Schedule 13D, filed 2026-07-02) and Baselake Partners, LP (7.3%, Schedule 13G, filed 2026-06-25).
Who are the largest shareholders of Passage BIO, Inc.?
By the share each holder's latest filing reports, the largest holders of Passage BIO, Inc. on this page are Lynx1 Capital Management LP (21%) and Baselake Partners, LP (7.3%).
When did Lynx1 Capital Management LP buy into Passage BIO, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13G/A, filed 2025-11-14, reporting 19.6%; its latest, Schedule 13D filed 2026-07-02, reports 21%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Passage BIO, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 6, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Passage BIO, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.